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Delivery of Vascular Endothelial Growth Factor
and Angiopoietin-1 Plasmid Deoxyribonucleic Acid
Alexandra H. Smith, MSC,* Michael A. Kuliszewski, BSC,* Christine Liao, BSC,*
Dmitriy Rudenko, BSC,* Duncan J. Stewart, MD,† Howard Leong-Poi, MD*
Toronto, Ontario, Canada
Objectives The aim of this study was to compare temporally separated vascular endothelial growth factor (VEGF) and angio-
poietin (Ang)-1 delivery with concomitant delivery or single VEGF delivery, for therapeutic angiogenesis in chronic
ischemia.
Background Single gene delivery of VEGF results in immature neovessels that ultimately regress. Endogenously, VEGF acts
early to initiate angiogenesis, whereas Ang-1 acts later to induce vessel maturation. Timing VEGF and Ang-1
gene delivery to mimic endogenous angiogenesis might be more effective for sustained neovascularization.
Methods Unilateral hindlimb ischemia was induced in 170 rats. Ultrasound-mediated gene delivery was performed with
cationic microbubbles and plasmid deoxyribonucleic acid. Groups included VEGF at 2 weeks, VEGF/Ang-1 at 2
weeks, VEGF at 2 weeks with Ang-1 at 4 weeks, and untreated control subjects. At 2, 4, and 8 weeks after liga-
tion, blood flow and flow reserve (FR) were assessed by contrast-enhanced ultrasound. Vascular density, organiza-
tion, and supporting cell coverage were assessed by fluorescent microangiography and immunohistochemistry.
Results In untreated control subjects, blood flow, FR, and vessel density remained reduced. The VEGF delivery improved
flow and vessel density at 4 weeks; however, FR remained low, supporting cell coverage was poor, and flow and
vessel density regressed by 8 weeks. The VEGF/Ang-1 co-delivery marginally increased flow and vessel density;
however, FR and supporting cell coverage improved. After temporally separated VEGF and Ang-1 delivery, blood
flow, vessel density, and FR increased and were sustained, with improved pericyte coverage at 8 weeks.
Conclusions In conclusion, temporally separated VEGF and Ang-1 gene therapy results in sustained and functional
neovascularization. (J Am Coll Cardiol 2012;59:1320–8) © 2012 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.12.025bCardiovascular gene therapy aimed at promoting new vessel
formation or angiogenesis for the treatment of refractory
coronary artery disease (CAD) and peripheral arterial dis-
ease (PAD) has been extensively studied (1). Although
advances in our understanding of the biology of new vessel
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2011, accepted December 15, 2011.growth has led to promising results of early open-labeled
human trials, the translation of the basic science of angio-
genesis into a clinically useful and widely applicable strategy
for therapeutic angiogenesis in patients has not yet occurred.
The largely disappointing results of randomized clinical
trials of gene therapy for ischemic CAD (2,3) and PAD (4)
can be attributed to several factors, including the choice of
the optimal biological agent, a limited time course of
treatment (usually single fixed dose), and suboptimal deliv-
ery techniques (5).
All large double-blind, randomized, placebo-controlled
clinical trials of gene therapy for angiogenesis have used a
1-time administration of a single therapeutic gene and have
failed to conclusively show significant benefit. Most recently,
oth the Euroinject One Trial (2) and the NORTHERN
NOGA angiogenesis Revascularization Therapy: assess-
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delivery system to percutaneously administer a single dose of
VEGF165 plasmid deoxyribonucleic acid (DNA) to ischemic
yocardium in “no-option” patients, showing no difference in
rimary efficacy endpoints between active treatment and pla-
ebo. The results of these studies suggest that VEGF might
ot be the ideal candidate for single gene therapy.
Angiopoietins (Ang) are another important class of
rowth factors specific for vascular endothelial cells that
nteract closely with VEGF (6). Although VEGF seems to be
mportant during the initiation phase of angiogenesis, increas-
ng permeability and degrading the extracellular matrix, Ang-1
s important late in the angiogenic process, contributing to
eovessel maturation (6). Accordingly, Ang-1 is a promising
andidate to compliment VEGF gene delivery. Given the
mportance of the temporal relationship between VEGF and
ng-1 during endogenous angiogenesis, the timeline of
ransfection of these growth factors during therapeutic
ngiogenesis might be important. Therefore, we hypothe-
ized that a strategy of temporally separated transfection
f VEGF and Ang-1, delivering VEGF early and Ang-1
ater, would result in a greater, more sustained, and
unctional angiogenic response, as compared with simul-
aneous delivery of VEGF and Ang-1 or VEGF alone.
e tested our hypothesis with a model of chronic
indlimb ischemia in rats.
ethods
etailed methods are available in the Online Appendix.
nimal preparation. The study protocol was approved by
he Animal Care and Use Committee at St. Michael’s
ospital Research Centre, University of Toronto. Proximal
indlimb ischemia was induced in 170 male Sprague-
awley rats (Charles River, Wilmington, Massachusetts) by
igation of the left common iliac artery (7,8).
icrobubble and DNA preparation. For contrast-
nhanced ultrasound (CEU) perfusion imaging, lipid-
helled perfluoropropane microbubbles were used. For gene
elivery, cationic lipid microbubbles were charge-coupled to
lasmid complementary DNA (500 g) (7,8). Plasmids
were constructed by incorporating the human VEGF165
gene into the vector pcDNA3.1() and the human Ang-1
gene into the vector pFLAG-CMV-1 (Addgene, Cam-
bridge, Massachusetts).
Gene delivery. Gene delivery to the proximal ischemic
hindlimb was performed by ultrasound-targeted micro-
bubble destruction (UTMD), as previously described (7–9).
For VEGF/Ang-1 early animals, Ang-1 was delivered 5
min after VEGF.
Perfusion imaging: CEU. Blood flow was measured in the
proximal hindlimb adductor muscles with CEU during
continuous intravenous infusion of perfusion microbubbles
(1  107 min1) (10). In brief, after background subtrac-
tion, contrast-enhanced images from multiple increasing
pulsing intervals (200 ms to 40 s) are used to generate wreplenishment curves, which are
analyzed to obtain parameters of
microvascular perfusion (10). For
the measurement of blood flow
reserve (FR), the ratio of exercise
blood flow to resting flow was
measured by CEU during elec-
trically stimulated muscle con-
traction (3 mA, pulse frequency 2
Hz) induced by a pulse generator
(AV Sequential Demand Pulse
Generator, Medtronic 5330,
Medtronic, Mississauga, On-
tario, Canada).
Fluorescent microangiography-
. Fluorescent microangiography
(FMA), a technique of postmor-
tem vascular casting, was per-
formed as previously described
(7–9). Vessel density was calcu-
lated from the total length of
vessels/tissue volume, and total
length of a vascular tree in 0.036
cm3 of tissue was quantified.
apillary and arteriolar density
as calculated by branch order analysis based on the
trahler Method (11) with Neurolucida Software package
MBF Bioscience, Williston, Vermont), as previously de-
cribed (9). Ischemic limbs were compared between groups at
and 8 weeks after ligation.
mmunohistochemistry. Immunohistochemical staining
as performed on hindlimb muscle, with antibodies against
on Willebrand Factor (Santa Cruz Biotechnology, Santa
ruz, California) (endothelial cells), alpha-smooth muscle
ctin (SMA) (Abbiotec, San Diego, California) (smooth
uscle cells), platelet-derived growth factor receptor
PDGFR)-beta, Abcam, Cambridge, Massachusetts) (peri-
ytes) and NG-2 (Abcam) (pericytes). Nuclei were counter-
tained with Topro-3 (blue).
eal-time polymerase chain reaction. At 3 days after
elivery (2 and 4 weeks after ligation) and 8 weeks after
igation, animals were sacrificed, and adductor muscle tissue
as isolated, ribonucleic acid was extracted, and real-time
olymerase chain reaction for exogenous Ang-1 and total
EGF expression was performed on complementary DNA
ith the housekeeping gene Cyclophylin, as previously
escribed (7–9).
xperimental protocol. Iliac artery ligation was performed
t Day 0. After 2 weeks, baseline perfusion and FR were
easured. Gene delivery was performed with UTMD as per
roup assignment—VEGF at 2 weeks after ligation (VEGF
lone), VEGF and Ang-1 co-delivery at 2 weeks (VEGF/
ng-1 early), or VEGF at 2 weeks and Ang-1 at 4 weeks
fter ligation (VEGF  Ang-1 late). Control animals were
ntreated. Blood flow and FR were reassessed at 4 and 8
Abbreviations
and Acronyms
Ang-1  angiopoietin-1
Ang-2  angiopoietin-2
CAD  coronary artery
disease
CEU  contrast-enhanced
ultrasound
DNA  deoxyribonucleic
acid
FMA  fluorescent
microangiography
FR  flow reserve
PAD  peripheral arterial
disease
PDGFR  platelet-derived
growth factor receptor
SMA  smooth muscle
actin
UTMD  ultrasound-
targeted microbubble
destruction
VEGF  vascular
endothelial growth factoreeks after ligation. Animals were sacrificed at 3 days after
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Temporally Separated Multi-Gene Delivery April 3, 2012:1320–8delivery and at 4 and 8 weeks after ligation to collect tissue
for postmortem analysis.
Statistical methods. Data are expressed as mean  SEM.
omparisons between groups and time points were made with
2-way analysis of variance (GraphPad Prism5, version 5.0a;
raphPad, La Jolla, California). When differences between
eans were found, Bonferroni correction was performed.
ifferences were considered significant when p  0.05.
esults
EGF and Ang-1 expression after gene delivery. Human
ng-1 messenger ribonucleic acid expression in Ang-1-
reated animals and total VEGF messenger ribonucleic acid
n VEGF-treated animals peaked 3 days after delivery in
heir respective groups and decreased by 8 weeks, confirm-
ng transient transgene expression (Fig. 1).
EU resting perfusion and FR. Representative CEU
erfusion images from each treatment group are shown in
igure 2A. In control untreated ischemic muscle, resting flow
emained reduced at all time-points after ligation (Fig. 2B).
elivery of VEGF at 2 weeks after ligation increased flow at 4
eeks (0.58  0.26 to 0.86  0.23, p  0.001), but flow
returned to baseline levels by 8 weeks. Blood flow increased
marginally after simultaneous VEGF/Ang-1 co-delivery
(0.69  0.13 at 4 weeks, p  NS vs. 2 weeks, p  0.05 vs.
Control at 4 weeks). After VEGF with Ang-1 late delivery,
resting blood flow increased 2 weeks after VEGF delivery and
remained elevated after Ang-1 delivery at 4 weeks (0.90 
0.21, p 0.001 vs. 2 weeks and vs. all other groups at 8 weeks).
Similar to changes in blood flow, blood volume increased after
VEGF single delivery in the VEGF alone (0.94  0.33 at 2
weeks to 1.21  0.33 at 4 weeks, p  0.01) and VEGF with
Ang-1 late groups (0.82  0.20 at 2 weeks to 1.30  0.43 at
4 weeks, p 0.001), but increases in blood volume persisted at
8 weeks only in the VEGF with late Ang-1 treated animals.
Figure 1 Gene Expression by Real-Time Polymerase Chain Rea
(Left) Expression of human angiopoietin (Ang)-1, compared with cyclophilin (Cyclo)
sion in all groups. Data from after 2-week delivery in white, after 4-week delivery i
weeks. #p  0.05, ##p  0.01 versus Control. mRNA  messenger ribonucleic aThe FR in normal limbs was 2.41  0.06 (Fig. 2C). In
control and VEGF alone animals, FR remained reduced at
all time-points. By comparison, FR improved after VEGF/
Ang-1 co-delivery and after temporally separated delivery of
VEGF and Ang-1.
Vessel density and vascular architecture by FMA. Rep-
resentative FMA images from each treatment group at 4
and 8 weeks are shown in Figure 3A. After delivery of
VEGF alone, vascular density (Fig. 3C) improved com-
pared with control at 4 weeks (p  0.001) but was not
sustained to 8 weeks. After VEGF/Ang-1 co-delivery,
vessel density was not significantly different from control
subjects. After VEGF with Ang-1 late delivery, vessel
density was elevated compared with all other treatment
groups (21,817  1,036 vessels/mm3 in VEGF with Ang-1
ate at 8 weeks, p  0.001 vs. Control and VEGF alone at
weeks, p  0.01 vs. VEGF/Ang-1 at 8 weeks). Changes
n total vascular length (Fig. 3B) were similar to vascular
ensity. Significant improvement was observed only after
EGF with Ang-1 late delivery, similar to vessel density.
After VEGF delivery, capillary density and arteriole
ensity increased, compared with control muscle at 4 weeks
capillary density p 0.001 vs. control; arteriole density p
.01 vs. control) (Figs. 4A and 4B). By 8 weeks, both
apillary and arteriole densities returned to baseline levels.
fter VEGF with Ang-1 late delivery, however, capillary
nd arteriole densities remained increased at 8 weeks (cap-
llary density p  0.05 vs. control and p  0.01 vs. VEGF
lone at 8 weeks; arteriole density p  0.001 vs. control and
 0.01 vs. VEGF alone at 8 weeks). In addition, after
emporally separated delivery of VEGF and Ang-1, arteri-
le/capillary ratio was significantly higher compared with
ontrol and VEGF alone-treated muscle at 8 weeks (0.81
.13 after VEGF with Ang-1 late vs. 0.68 0.03 in control
nd vs. 0.67  0.10 after VEGF alone, both p  0.05).
-1-treated groups. (Right) Total vascular endothelial growth factor (VEGF) expres-
, and at 8 weeks after ligation in black. Mean  SEM. **p  0.01 versus 8
A1  vascular endothelial growth factor/angiopoietin 1; wk  week.ction
in Ang
n grey
cid; V/
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April 3, 2012:1320–8 Temporally Separated Multi-Gene DeliveryArteriolar density and mural cell coverage by immuno-
fluorescence. Late (8 weeks after ligation) after gene de-
livery, increased alpha-SMA-positive arterioles were found
in VEGF with Ang-1 late-treated ischemic muscle
(Fig. 4C). The PDGFR-beta and NG-2 expressing peri-
cytes were increased in the VEGF/Ang-1 early and VEGF
Ang-1 late groups, compared with control and VEGF
groups, with the greatest co-localization of von Willebrand
factor-positive endothelial cells and pericytes expressing
PDGFR-beta and NG-2 seen after temporally separated
Figure 2 Contrast-Enhanced Ultrasound Perfusion Data
(A) Representative contrast-enhanced ultrasound images at three pulsing intervals
ment groups at 8 weeks after ligation. Contrast signal increases at a faster rate a
blood flow. (B) Resting blood flow in the ischemic hindlimb adductor muscles norm
0.001 versus 2 weeks and control. #p  0.05 versus control. ###p  0.001 vers
and 8 weeks after ligation. Dotted line highlights normal flow reserve. Mean  SE
Abbreviations as in Figure 1.VEGF  Ang-1 delivery (Fig. 5).Discussion
Clinical trials of VEGF gene therapy for therapeutic angio-
genesis in CAD and PAD have yielded disappointing
results. One of the major limitations of “first generation”
angiogenic factors like VEGF is that resultant neovessels are
immature and poorly formed (12,13), and might regress.
Our previous studies using UTMD to deliver VEGF
plasmid DNA to ischemic skeletal muscle (7,8) and the
results of our present study support this, with an increase in
blood flow and vessel density 2 weeks after VEGF delivery
, 7 s, and 20 s (top to bottom) of the proximal ischemic hindlimb for all 4 treat-
s a higher plateau in the VEGFAng-1 late-treated muscle, signifying greater
to contralateral limb at 2, 4, and 8 weeks after ligation. Mean  SEM. ***p 
other groups at 8 weeks. (C) Flow reserve in the ischemic hindlimbs at 2, 4,
p  0.01, ***p  0.001 versus 2 weeks. #p  0.05 versus control and VEGF.—1 s
nd ha
alized
us all
M. **that does not persist at later time points. Delivery of Ang-1
1324 Smith et al. JACC Vol. 59, No. 14, 2012
Temporally Separated Multi-Gene Delivery April 3, 2012:1320–8plasmid DNA 2 weeks after VEGF delivery results in a
sustained improvement in blood flow and vessel density and
augmentation of blood FR. Our study demonstrates that a
strategy of temporally separated multi-gene delivery of
VEGF and Ang-1, based on the temporal pattern of growth
factor expression during endogenous angiogenesis, results in
a more sustained and functional angiogenic response.
Limitations of VEGF single delivery. Although pre-
clinical studies of VEGF for therapeutic angiogenesis have
shown consistent increases in blood flow and vessel density
(7,8,14), studies that measured angiogenic outcomes at 4
weeks after delivery often found late regression (7,8,11,15).
Disorganized, leaky neovasculature after increased VEGF
expression has been noted in several studies of therapeutic
angiogenesis (12,13,16,17). Some trimming of excessive
neovascularization normally accompanies angiogenesis (18),
likely related to endothelial cell apoptosis upon withdrawal
of pro-angiogenic factors (19) and reduced shear stress due
to disorganized branching (20). In our study, FR did not
Figure 3 Representative Fluorescent Microangiography Images
(A) Representative fluorescent microangiography images at 4 and 8 weeks after li
8 weeks after ligation. (C) Vascular density/tissue volume. Mean  SEM. *p  0
0.01 versus V/A1 early. Abbreviations as in Figure 1.improve after VEGF single delivery, suggesting the newvasculature lacked the capacity to respond to increased
oxygen demand. Our findings suggest that the lack of
functional FR in VEGF-induced vasculature might be due
to poor supporting cell coverage (21) and disorganized
collateralization.
Temporal regulation of endogenous angiogenesis. Simi-
lar to VEGF, the angiopoietins, Ang-1 and Ang-2, are a
major class of angiogenic cytokines specific for vascular
endothelial cells (6). Ang-1 has only a modest influence on
vessel growth (6,11,22–24), in contrast to the potent angio-
genic effect of VEGF; however, Ang-1 plays an integral role
in vascular remodeling and maturation (6). Although
VEGF causes vascular instability and increased permeabil-
ity, Ang-1 stabilizes vessels, increases pericyte coverage, and
decreases vascular leakage (22,25,26). The VEGF and
Ang-2 initiate angiogenesis, acting synergistically to in-
crease permeability and degrade the extracellular matrix.
Ang-2 inhibits Tie-2 phosphorylation (27), blocking the
stabilizing actions of Ang-1 and facilitating VEGF
Total Vascular Length and Density/Tissue Volume
. (B) Total vascular length (mm)/tissue volume (mm3) in ischemic limbs at 4 and
*p  0.01, ***p  0.001 versus Control. ###p  0.001 versus VEGF. p and
gation
.05, *action in the initiation of angiogenesis. Ang-1 seems to
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to stabilization and maturation of neovessels (27), while
opposing VEGF (22).
Combination VEGF and Ang-1 gene therapy for angio-
genesis. Due to the different yet complementary roles of
these 2 angiogenic growth factors in angiogenesis, their
co-administration has been previously studied. Interest-
ingly, studies of simultaneous delivery of VEGF with Ang-1
have shown conflicting results; some show benefit (24,28),
whereas others show that dual delivery is less effective
compared with single VEGF delivery (15,23,29). Viral gene
delivery of VEGF/Ang-1 after myocardial infarction in
diabetic rats increases capillary/arteriolar density after 1
week (28); however, an incremental angiogenic effect above
VEGF alone is not observed in rat hindlimb ischemia (23).
n a rabbit ischemic hindlimb model, combination VEGF/
ng-1 gene delivery produced only a modest effect on
esting blood flow and capillary formation, as compared
ith either factor alone (24). Our study has clarified the
Figure 4 Capillary and Arteriole Densities by Fluorescent Micro
(A) Number of capillaries (order 0 vessels)/tissue volume (mm3). (B) Number of a
numbered and color-coded by branch order. White arrow indicates direction of flow
versus VEGF. p  0.05, p  0.001 versus V/A1 early. (C) Immunostaining o
ligation—smooth muscle actin (SMC) (magenta) and Topro-3 nuclei (blue), showin
tions as in Figure 1.attern emerging from previous multi-gene studies that VEGF/Ang-1 co-delivery causes a significant yet modest
nd transient increase in resting blood flow and vessel
ensity.
The limitation of using VEGF and Ang-1 simultane-
usly might relate to the ability of Ang-1 to disrupt the ideal
icroenvironment of VEGF. Studies using transgenic mice
ave clearly demonstrated that Ang-1 can act as a negative
egulator of VEGF-induced angiogenesis in the heart (30).
ndeed, late in the angiogenic process, Ang-1 binds to Tie-2
n endothelial cells to induce vessel maturation by matrix
eposition, increasing intercellular interactions and reducing
ascular permeability (25), counteracting VEGF-mediated ef-
ects. The VEGF-induced blood-brain barrier permeability is
ssociated with increased matrix metalloproteinase-9 activity,
ith both effects being decreased by Ang-1 therapy, sug-
esting that Ang-1 attenuation of VEGF effects might in
art be mediated through matrix metalloproteinase-9 (31).
ur study results indicate that, when VEGF and Ang-1 are
elivered simultaneously, Ang-1 stabilization impedes
graphy and Immunostaining
es (order 1 to order 3 vessels)/tissue volume. (Right, top) Vascular tracing
n  SEM. *p  0.05, **p  0.01, ***p  0.001 versus Control. ##p  0.01
rioles from ischemic muscle from each treatment group at 8 weeks after
test arteriolar density in VEGFAng1 late-treated ischemic muscle. Abbrevia-angio
rteriol
. Mea
f arte
g greaEGF vessel formation, leading to more modest increases
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Temporally Separated Multi-Gene Delivery April 3, 2012:1320–8in resting perfusion as compared with VEGF alone. How-
ever, we noted an increase in blood FR in animals co-treated
with VEGF and Ang-1 plasmid DNA, corresponding to
increased vascular network maturation with improved sup-
porting cell coverage, supporting a predominant Ang-1
effect. This supports some of the previously reported bene-
ficial effects of co-administration (29), benefits that are
enhanced even further when delivered separately in a tem-
poral fashion.
This study revealed that the key to taking maximal
advantage of each growth factor is to mimic the endogenous
timeline of gene expression (27,32). Only 2 studies to date
have attempted to test this hypothesis. Yamauchi et al. (33)
studied temporal combinations of VEGF and Ang-1 gene
delivery in a rabbit ischemic hindlimb model. Although they
Figure 5 Representative Images From Normal Adductor Muscle
Each Treatment Group at 8 Weeks After Ligation, Dem
von Willebrand factor (vWF) (Santa Cruz Biotechnology, Santa Cruz, California)-end
bar  100 m. (B) Pericyte coverage, platelet-derived growth factor receptor (PDG
either (A) NG2 (Abcam, Cambridge, Massachusetts) or (B) PDGFR-beta. Abbreviatconcluded that pre-administration of Ang-1 followed 5 dayslater by VEGF induced the greatest functional vascular
formation, the results do not fully support their conclusions.
Angiographic scores were highest in the VEGF-alone
group, compared with other groups, whereas vessel density
and laser Doppler perfusion measurements varied widely.
Ang-1 followed by VEGF was significantly greater than
control, yet there were no significant differences between
dual-treatment groups, including Ang-1 followed by
VEGF, VEGF/Ang-1 co-administration, and VEGF fol-
lowed by Ang-1. Differences in gene delivery methods
(intramuscular vs. ultrasound-mediated [8]), perfusion as-
sessment technique, and timing of sequential gene delivery
(5 vs. 14 days) might have accounted for differences in study
findings. Importantly, we chose to deliver Ang-1 at Day 14
after VEGF, a time-point after delivery when exogenous
Ischemic Muscle From
trating Supporting Cell Coverage
l cells (red) and Topro-3-nuclei (blue). (A) Pericyte coverage, NG2 (green). Scale
ta (green). Scale bar  20 m. Yellow indicates co-localization of vWF and
s in Figure 1.and
ons
othelia
FR)-be
ions aVEGF expression becomes undetectable (7,8), thus avoid-
11
1
1
1
1
1
1
1
1
2
2
1327JACC Vol. 59, No. 14, 2012 Smith et al.
April 3, 2012:1320–8 Temporally Separated Multi-Gene Deliverying any competing effects of VEGF on Ang-1 therapy. The
5-day period between delivery of Ang-1 and VEGF in the
study by Yamauchi et al. (33) likely results in simultaneously
active VEGF and Ang-1 gene expression in all their
dual-treatment groups, possibly accounting for the lack of
differences between groups.
Peirce et al. (11) used a dorsal skinfold backpack window
chamber to evaluate vascular pattern changes in response to
focally delivered recombinant VEGF and Ang-1 protein
with intravital microscopy. The VEGF delivery resulted in
increased density of vessels out to 14 days but was reduced
to control levels by Day 21. Ang-1 protein delivery resulted
in lesser increases in vessel density when compared with
VEGF alone. The addition of recombinant Ang-1 on Day
7 after VEGF delivery resulted in sustained increases out to
Day 21, vessel branch order ratios comparable to control
levels, and increased alpha-SMA-positive vessels (11). Our
study results confirm and extend these findings in a clinically
relevant model of chronic hindlimb ischemia. Early VEGF
delivery increased resting flow by increasing vessel density.
Late (14 days) Ang-1 delivery stabilized vessels by providing
peri-endothelial support (pericytes and smooth muscle cells)
and improving arteriole/capillary ratio. The organized vas-
culature, improved supporting cell coverage, and the recog-
nized ability of Ang-1 to reduce vascular permeability (26)
generate a sustained improvement in both resting blood
flow and FR. In this respect, Ang-1 mimics the function of
the direct pericyte chemo-attractant PDGF-beta, which
also results in maturation of VEGF-induced neovascular-
ization (34).
Conclusions
We have demonstrated that amplifying growth factor ex-
pression according to endogenous timelines allows for an
early VEGF-induced increase in blood vessel growth and a
late Ang-1–induced improvement in vascular stabilization
and supporting cell coverage, resulting in a long-lasting
improvement in resting blood flow and FR. This suggests a
new paradigm for angiogenic gene therapy, whereby not
only the right combinations of therapeutic genes but also
the timing of delivery and action need to be considered to
achieve an optimal therapeutic response.
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